TY - JOUR

T1 - COVID-19 severity and mortality in patients with CLL

T2 - an update of the international ERIC and Campus CLL study

AU - Chatzikonstantinou, Thomas

AU - Kapetanakis, Anargyros

AU - Scarfò, Lydia

AU - Karakatsoulis, Georgios

AU - Allsup, David

AU - Cabrero, Alejandro Alonso

AU - Andres, Martin

AU - Antic, Darko

AU - Baile, Mónica

AU - Baliakas, Panagiotis

AU - Bron, Dominique

AU - Capasso, Antonella

AU - Chatzileontiadou, Sofia

AU - Cordoba, Raul

AU - Correa, Juan Gonzalo

AU - Cuéllar-García, Carolina

AU - De Paoli, Lorenzo

AU - De Paolis, Maria Rosaria

AU - Del Poeta, Giovanni

AU - Demosthenous, Christos

AU - Dimou, Maria

AU - Donaldson, David

AU - Doubek, Michael

AU - Efstathopoulou, Maria

AU - Eichhorst, Barbara

AU - El-Ashwah, Shaimaa

AU - Enrico, Alicia

AU - Espinet, Blanca

AU - Farina, Lucia

AU - Ferrari, Angela

AU - Foglietta, Myriam

AU - Frederiksen, Henrik

AU - Fürstenau, Moritz

AU - García-Marco, José A.

AU - García-Serra, Rocío

AU - Gentile, Massimo

AU - Gimeno, Eva

AU - Glenthøj, Andreas

AU - Gomes da Silva, Maria

AU - Gutwein, Odit

AU - Hakobyan, Yervand K.

AU - Herishanu, Yair

AU - Hernández-Rivas, José Ángel

AU - Herold, Tobias

AU - Innocenti, Idanna

AU - Itchaki, Gilad

AU - Jaksic, Ozren

AU - Janssens, Ann

AU - Kalashnikova, Оlga B.

AU - Kalicińska, Elżbieta

AU - Karlsson, Linda Katharina

AU - Kater, Arnon P.

AU - Kersting, Sabina

AU - Labrador, Jorge

AU - Lad, Deepesh

AU - Laurenti, Luca

AU - Levin, Mark David

AU - Lista, Enrico

AU - Lopez-Garcia, Alberto

AU - Malerba, Lara

AU - Marasca, Roberto

AU - Marchetti, Monia

AU - Marquet, Juan

AU - Mattsson, Mattias

AU - Mauro, Francesca R.

AU - Milosevic, Ivana

AU - Mirás, Fatima

AU - Morawska, Marta

AU - Motta, Marina

AU - Munir, Talha

AU - Murru, Roberta

AU - Niemann, Carsten U.

AU - Rodrigues, Raquel Nunes

AU - Olivieri, Jacopo

AU - Orsucci, Lorella

AU - Papaioannou, Maria

AU - Pavlovsky, Miguel Arturo

AU - Piskunova, Inga

AU - Popov, Viola Maria

AU - Quaglia, Francesca Maria

AU - Quaresmini, Giulia

AU - Qvist, Kristian

AU - Reda, Gianluigi

AU - Rigolin, Gian Matteo

AU - Ruchlemer, Rosa

AU - Saghumyan, Gevorg

AU - Shrestha, Amit

AU - Šimkovič, Martin

AU - Špaček, Martin

AU - Sportoletti, Paolo

AU - Stanca, Oana

AU - Stavroyianni, Niki

AU - Tadmor, Tamar

AU - Te Raa, Doreen

AU - Tonino, Sanne H.

AU - Trentin, Livio

AU - Van Der Spek, Ellen

AU - van Gelder, Michel

AU - van Kampen, Roel

AU - Varettoni, Marzia

AU - Visentin, Andrea

AU - Vitale, Candida

AU - Wasik-Szczepanek, Ewa

AU - Wróbel, Tomasz

AU - San Segundo, Lucrecia Yáñez

AU - Yassin, Mohamed

AU - Coscia, Marta

AU - Rambaldi, Alessandro

AU - Montserrat, Emili

AU - Foà, Robin

AU - Cuneo, Antonio

AU - Stamatopoulos, Kostas

AU - Ghia, Paolo

N1 - Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

AB - Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

U2 - 10.1038/s41375-021-01450-8

DO - 10.1038/s41375-021-01450-8

M3 - Journal article

C2 - 34725454

AN - SCOPUS:85118404639

VL - 35

SP - 3444

EP - 3454

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -